Mark Edward Stella,John Richard Entwisle,Baltej Ludher,Jonathan E. Clark,Daren K. Aness,Guhan Balan,Andrew Nicholas Carr
申请号：
US15713746
公开号：
US20180085317A1
申请日:
2017.09.25
申请国别(地区):
US
年份:
2018
代理人:
摘要：
A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours.
